Migraine Drugs: May Repeat To Bring Success For Rheumatoid Arthritis Disease

  • comments
  • print
  • email
Dec 30, 2016 11:19 AM EST

Rheumatoid arthritis (RA) is an autoimmune joint disorder disease that causes chronic joint inflammation to the joints and other areas of the body such as the lungs, eyes, skin, and heart.

Rheumatoid arthritis that begins in people under 16 years of age. People with Rheumatoid arthritis may experience an increase in symptoms which is called flares and that can last for days or weeks. Almost two decades ago, several drugs to treat rheumatoid arthritis came in a market for the treatment of the autoimmune joint disorder disease. But, these drugs are made using living cells and went to the blockbuster sales.

The four pharma heavyweights including Amgen Inc as well as some smaller drug developer Alder Biopharmaceuticals Inc want to bring their biologics to market. The first three rheumatoid arthritis (RA) biologics made drugs using living cells and they were approved between 1998 and 2002, starting with Amgen's Enbrel.

These drugs were also approved for other autoimmune conditions, which in part went to the notch of blockbuster sales. The migraine treatments could also be used in other disorders characterized by headaches. Many Migraine patients are currently treated with lot of drugs including anti-depressants, hypertension medicines - with little success.

About 40 million of peoples suffer from migraines and other 13 million of people are afflicted with a severe form of the disease. Amgen, which is developing its migraine drug in collaboration with Novartis AG, said last month the medicine is succeeded in a second late-stage study. Biologics are more expensive than traditional drugs but Amgen may end up pricing their migraine treatments more conservatively to avoid regulatory.

The two other companies Eli Lilly, Teva Pharmaceutical Industries Ltd was developing similar drugs is expected in 2017 and 2018 by Late-stage data. The migraine drug market is expected to increase to more than $10 billion in 2025 from about $3 billion in 2015.

Join the Conversation
Real Time Analytics